MK-677 (Ibutamoren)

MK-677, also known as Ibutamoren or Ibutamoren Mesylate, is not a peptide. It is a non-peptide, orally active small molecule with the chemical name 2-amino-2-methyl-N-[1-(1-methylsulfonylspiro[2H-indene-1,4'-piperidine]-6-yl)but-2-enyl]-propanamide methanesulfonate. Its molecular weight is 528.67 Da, CAS number 159752-10-0, and molecular formula C27H36N4O5S. It functions as a potent, selective agonist of the growth hormone secretagogue receptor (GHSR-1a), the same receptor activated by the endogenous hormone ghrelin. Its oral bioavailability distinguishes it from all peptide-based GH secretagogues, which require injection.

MK-677 mimics ghrelin's action at the pituitary level, binding to GHSR-1a receptors on somatotroph cells and triggering GH release through the phospholipase C/IP3/DAG signaling cascade. Unlike exogenous GH, MK-677 preserves the natural pulsatile pattern of GH secretion, amplifying both the frequency and amplitude of GH pulses over a sustained 24-hour period following a single oral dose. It also increases GH release from the hypothalamus by stimulating GHRH neurons and suppressing somatostatin tone, creating a multi-level amplification of the GH axis. Importantly, MK-677 does not suppress the hypothalamic-pituitary axis, meaning endogenous GH production is enhanced rather than replaced.

The clinical evidence for MK-677 is unusually strong for a compound in this category. A landmark 2-year randomized, double-blind, placebo-controlled trial (Nass et al., Annals of Internal Medicine, 2008, N=65 healthy elderly adults aged 60-81) demonstrated that 25 mg/day MK-677 restored GH and IGF-1 secretory profiles to levels characteristic of healthy young adults. IGF-1 increased by approximately 40% and remained elevated throughout the 2-year study without tolerance development. Fat-free mass increased by 1.6 kg versus placebo. A separate study (Copinschi et al., Neuroendocrinology, 1997, N=8) demonstrated that MK-677 increased Stage IV (deep) sleep duration by 50% and REM sleep by 20%, improvements that were sustained throughout the 2-week study period. Murphy et al. (J Clin Endocrinol Metab, 1998, N=32 obese males) showed improved nitrogen balance within 7 days of treatment, indicating enhanced protein synthesis and potential anti-catabolic effects.

Pharmacokinetically, MK-677 is rapidly absorbed after oral administration, reaching peak plasma concentrations within 1-2 hours. Its effective half-life is approximately 4-6 hours, but the duration of GH elevation extends to a full 24 hours due to downstream signaling amplification and the sustained nature of the pituitary response. MK-677 is metabolized primarily by CYP3A4 in the liver, and its metabolites are excreted renally. Steady-state plasma concentrations are reached within 3 days of once-daily dosing. There are no clinically significant drug-drug interactions documented at standard doses, though theoretical interactions with strong CYP3A4 inhibitors (ketoconazole, ritonavir) or inducers (rifampin, carbamazepine) should be considered.

MK-677 is supplied as an oral liquid solution and should be stored at room temperature (15-25C), protected from light. The solution is stable for at least 12 months when stored properly. No reconstitution is necessary. The solution should be measured with the provided graduated dropper for accurate dosing. Unlike peptides, MK-677 does not require refrigeration and is not sensitive to temperature fluctuations within the normal room temperature range, making it considerably easier to store and transport than injectable peptides.

Published research protocols have primarily used MK-677 at doses of 10-25 mg once daily, taken orally. The 25 mg dose is the most commonly studied and has produced the most strong GH and IGF-1 elevations. Some protocols use 10-12.5 mg for extended periods to minimize appetite stimulation while maintaining meaningful IGF-1 elevation. Dosing is typically performed at bedtime to take advantage of the compound's sleep-enhancing effects and to align the amplified GH pulse with the natural nocturnal GH surge. Studies have used continuous daily dosing for up to 2 years without loss of efficacy.

The safety profile of MK-677 has been characterized across multiple clinical trials involving several hundred subjects. The most commonly reported side effects are increased appetite (consistent with ghrelin receptor activation), mild water retention and transient edema in the first 1-2 weeks, and occasional muscle cramping. The 2-year Nass et al. study found no significant adverse effects on fasting glucose at the 25 mg dose, though there was a transient increase in fasting glucose in some subjects during the first 2 months that normalized by month 6. Insulin sensitivity should be monitored, particularly in subjects with pre-existing insulin resistance or metabolic syndrome. MK-677 does not suppress the HPA axis, does not raise cortisol or prolactin at standard doses, and has no documented hepatotoxicity. It was well tolerated across all published clinical trials.